Cadwalader Names Wes Misson as Co-Managing Partner
"In recent months, Wes has been serving alongside me effectively as Co-Managing Partner, and I am thrilled that he has agreed to formally take on the role," said Pat. "In addition to leading and continuously growing one of our largest and most profitable practice groups, Wes's character, integrity, tireless work ethic and commitment to Cadwalader are qualities that he's known and admired for across the firm. As one of our next generation leaders, he is laser-focused on our long-term success."
Wes chairs Cadwalader's Finance group, serves on its Management Committee, and leads the firm's Fund Finance practice, a trans-Atlantic group that is the largest and most experienced fund finance team in the market. He will continue to maintain his own active practice, for which he has repeatedly been recognized for delivering results for clients by The Financial Times, The American Lawyer, Chambers USA, IFLR1000, North Carolina Lawyers Weekly and the Fund Finance Association which, in honoring Wes with its 2023 "Annual Contribution to the Industry Award," noted that his "innovative work and commercial approach has had a profound impact on the fund finance industry."
"Our market dominance in core practice areas, our decades-long relationships with the world's largest financial institutions, and our dedicated, elite lawyers have put us on track to have one of the best years in our history, with revenues projected to be over
View original content to download multimedia:https://www.prnewswire.com/news-releases/cadwalader-names-wes-misson-as-co-managing-partner-302570029.html
SOURCE Cadwalader, Wickersham & Taft LLP
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026
- Binance Coin Price Today: BNB Near $733 as Binance US Pursues Prediction Markets and Remittix Plans Its Next Price Step
- Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share